Skip to main content
Premium Trial:

Request an Annual Quote

RXi Q1 Loss Rises on Opko Deal Charge


RXi Pharmaceuticals this week reported its first-quarter financial results, posting a sharply increased net loss on a one-time charge associated with its purchase of the RNAi drug assets of Opko Health in early March.

For the three-month period ended March 31, RXi’s net loss was $14.4 million, compared with $1.9 million in the same quarter a year earlier. Driving the loss was a $12.3 million charge related to the fair value of RXi common shares issued to Opko under the companies’ deal (GSN 3/7/2013).

RXi’s revenues were $100,000, versus no revenues in the year-ago period, and reflect money received under government grants.

Research and development spending surged to $13.8 million from $1.2 million, primarily due to the charge associated with the Opko deal, while general and administrative expenses fell $100,000 to $700,000.

At the end of the first quarter, RXi had cash and cash equivalents totaling $19.6 million.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.